BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Chimerix, Inc. Presents at Annual EBMT Meeting: Antiviral Activity of CMX001 in Patients With Life-Threatening Viral Infections


4/29/2013 11:36:39 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

DURHAM, N.C., April 29, 2013 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, announced today the presentation of the first clinical outcomes data on the use of CMX001 in patients with life-threatening infection with adenovirus (AdV), a disease with no approved therapy. The data were presented at the European Group for Blood and Marrow Transplantation's (EBMT) Annual Meeting held April 7 - 10 in London, England. CMX001 is an investigational oral nucleotide analog lipid-conjugate that has a broad spectrum of antiviral activity against double-stranded DNA (dsDNA) viruses.

Help employers find you! Check out all the jobs and post your resume.


Read at GlobeNewswire

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES